Literature DB >> 23597414

Treatment planning in molecular radiotherapy.

Gerhard Glatting1, Manuel Bardiès, Michael Lassmann.   

Abstract

In molecular radiotherapy a radionuclide or a radioactively labelled pharmaceutical is administered to the patient. Treatment planning therefore comprises the determination of activity to administer. This administered activity should maximize tumour cell sterilization while minimizing normal tissue damage. In this work we present different approaches that are frequently used for determining the suitable activity. These approaches may be cohort- based as in chemotherapy, or patient-specific using dosimetry based on individual biokinetics. The approaches are different with respect to the input complexity, the corresponding costs and - in consequence - the quality of the therapy. In addition, a general scheme for data collection and analysis is proposed. To develop an effective and safe treatment, elaborate data need to be obtained. The main challenges, however, are collecting these complex data and analyse them properly.
Copyright © 2013. Published by Elsevier GmbH.

Entities:  

Keywords:  Dosimetrie; Molekulare Radiotherapie; Nuklearmedizin; Radionuklidtherapie; Therapieplannung; Therapy planning; dosimetry; molecular radiotherapy; nuclear medicine; targeted radionuclide therapy

Mesh:

Substances:

Year:  2013        PMID: 23597414     DOI: 10.1016/j.zemedi.2013.03.005

Source DB:  PubMed          Journal:  Z Med Phys        ISSN: 0939-3889            Impact factor:   4.820


  9 in total

1.  The role of patient-based treatment planning in peptide receptor radionuclide therapy.

Authors:  Deni Hardiansyah; Christian Maass; Ali Asgar Attarwala; Berthold Müller; Peter Kletting; Felix M Mottaghy; Gerhard Glatting
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-11-18       Impact factor: 9.236

2.  Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer.

Authors:  Levent Kabasakal; Mohammad AbuQbeitah; Aslan Aygün; Nami Yeyin; Meltem Ocak; Emre Demirci; Turkay Toklu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-07-31       Impact factor: 9.236

3.  DNA damage in blood lymphocytes in patients after (177)Lu peptide receptor radionuclide therapy.

Authors:  Uta Eberlein; Carina Nowak; Christina Bluemel; Andreas Konrad Buck; Rudolf Alexander Werner; Harry Scherthan; Michael Lassmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-06-06       Impact factor: 9.236

4.  Monte Carlo Calculation of Radioimmunotherapy with (90)Y-, (177)Lu-, (131)I-, (124)I-, and (188)Re-Nanoobjects: Choice of the Best Radionuclide for Solid Tumour Treatment by Using TCP and NTCP Concepts.

Authors:  S Lucas; O Feron; B Gallez; B Masereel; C Michiels; T Vander Borght
Journal:  Comput Math Methods Med       Date:  2015-06-02       Impact factor: 2.238

5.  Dependence of treatment planning accuracy in peptide receptor radionuclide therapy on the sampling schedule.

Authors:  Christian Maaß; Jan Philipp Sachs; Deni Hardiansyah; Felix M Mottaghy; Peter Kletting; Gerhard Glatting
Journal:  EJNMMI Res       Date:  2016-03-25       Impact factor: 3.138

6.  Common strategic research agenda for radiation protection in medicine.

Authors: 
Journal:  Insights Imaging       Date:  2017-02-15

7.  A population-based method to determine the time-integrated activity in molecular radiotherapy.

Authors:  Deni Hardiansyah; Ade Riana; Peter Kletting; Nouran R R Zaid; Matthias Eiber; Supriyanto A Pawiro; Ambros J Beer; Gerhard Glatting
Journal:  EJNMMI Phys       Date:  2021-12-14

8.  Marker-controlled watershed with deep edge emphasis and optimized H-minima transform for automatic segmentation of densely cultivated 3D cell nuclei.

Authors:  Tuomas Kaseva; Bahareh Omidali; Eero Hippeläinen; Teemu Mäkelä; Ulla Wilppu; Alexey Sofiev; Arto Merivaara; Marjo Yliperttula; Sauli Savolainen; Eero Salli
Journal:  BMC Bioinformatics       Date:  2022-07-21       Impact factor: 3.307

9.  Application of machine learning to pretherapeutically estimate dosimetry in men with advanced prostate cancer treated with 177Lu-PSMA I&T therapy.

Authors:  Song Xue; Andrei Gafita; Chao Dong; Yu Zhao; Giles Tetteh; Bjoern H Menze; Sibylle Ziegler; Wolfgang Weber; Ali Afshar-Oromieh; Axel Rominger; Matthias Eiber; Kuangyu Shi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-06-30       Impact factor: 10.057

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.